Prokineticin 2 Is a Hypothalamic Neuropeptide That Potently Inhibits Food Intake by Gardiner, JV et al.
Prokineticin 2 Is a Hypothalamic Neuropeptide That
Potently Inhibits Food Intake
James V. Gardiner,1 Attia Bataveljic,1 Neekhil A. Patel,1 Gavin A. Bewick,1 Debabrata Roy,1
Daniel Campbell,1 Hannah C. Greenwood,1 Kevin G. Murphy,1 Saira Hameed,1 Preeti H. Jethwa,2
Francis J.P. Ebling,2 Steven P. Vickers,3 Sharon Cheetham,3 Mohammad A. Ghatei,1
Stephen R. Bloom,1 and Waljit S. Dhillo1
OBJECTIVE—Prokineticin 2 (PK2) is a hypothalamic neu-
ropeptide expressed in central nervous system areas known to
be involved in food intake. We therefore hypothesized that PK2
plays a role in energy homeostasis.
RESEARCH DESIGN AND METHODS—We investigated the
effect of nutritional status on hypothalamic PK2 expression and
effects of PK2 on the regulation of food intake by intracerebro-
ventricular (ICV) injection of PK2 and anti-PK2 antibody. Subse-
quently, we investigated the potential mechanism of action by
determining sites of neuronal activation after ICV injection of
PK2, the hypothalamic site of action of PK2, and interaction
between PK2 and other hypothalamic neuropeptides regulating
energy homeostasis. To investigate PK2’s potential as a therapeu-
tic target, we investigated the effect of chronic administration in
lean and obese mice.
RESULTS—Hypothalamic PK2 expression was reduced by fast-
ing. ICV administration of PK2 to rats potently inhibited food
intake, whereas anti-PK2 antibody increased food intake, sug-
gesting that PK2 is an anorectic neuropeptide. ICV administra-
tion of PK2 increased c-fos expression in proopiomelanocortin
neurons of the arcuate nucleus (ARC) of the hypothalamus. In
keeping with this, PK2 administration into the ARC reduced food
intake and PK2 increased the release of -melanocyte–stimulat-
ing hormone (-MSH) from ex vivo hypothalamic explants. In
addition, ICV coadministration of the -MSH antagonist agouti-
related peptide blocked the anorexigenic effects of PK2. Chronic
peripheral administration of PK2 reduced food and body weight
in lean and obese mice.
CONCLUSIONS—This is the first report showing that PK2 has
a role in appetite regulation and its anorectic effect is mediated
partly via the melanocortin system. Diabetes 59:397–406, 2010
Prokineticin 2 (PK2) is an 81–amino acid cysteine-rich protein structurally related to prokineticin 1(PK1), with which it shares 44% sequence homol-ogy (1–3). Both bind to two related G-protein–
coupled receptors, termed prokineticin receptor 1 (PKR1)
and prokineticin receptor 2 (PKR2) (4–6). The prokine-
ticins are so called because the first effect ascribed to them
was the stimulation of guinea pig ileum smooth muscle
contraction (2). Subsequently, PK2 has been shown to be
involved in several developmental and physiological pro-
cesses (7). It is thought to be critical for the development
of the central nervous system (CNS) because mice lacking
either PK2 or PKR2 have poorly developed olfactory bulbs
(8–10). In addition, these mice have hypogonadotrophic
hypogonadism due to abnormal gonadotrophin-releasing
hormone neuronal migration (3,11). The same phenotype
occurs in humans with mutations of PK2 or PKR2 (11–13).
PK2 is expressed in several regions of the adult brain but
is found in highest concentrations in the suprachiasmatic
nucleus (SCN), the site of the master circadian oscillator.
PK2 expression in the SCN varies with timing of the circadian
cycle (14). These data suggest a role for PK2 in the regulation
of the circadian clock (15). In accordance with this, mice
with targeted deletion of either PK2 or PKR2 exhibit alter-
ations in the circadian control of locomotor activity, thermo-
regulation, and sleep (16,17). Thus, PK2 may act as an output
molecule for the SCN circadian clock (18).
The hypothalamus is important in the regulation of
energy homeostasis. Because PK2 receptors are expressed
in hypothalamic nuclei known to regulate appetite (19,20),
we hypothesized that PK2 may play a role in the control of
appetite regulation. Indeed, intracerebroventricular (ICV)
administration of an amphibian homologue of PK2 (Bv8)
reduces food intake in rats (19). However, there are
currently no reports of the effects of PK2 on appetite. We
therefore investigated the role of PK2 in the control of
energy homeostasis. Our data suggest that PK2 is a novel
hypothalamic regulator of food intake.
RESEARCH DESIGN AND METHODS
Materials. PK2 was purchased from Peprotech (London, U.K.), PK2 antibody
was purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and control
IgG was generated from a random sequence peptide epitope (21).
Wistar rats and C57BL/6 mice. Adult male Wistar rats weighing 200–250 g
and adult male C57BL/6 mice weighing 20–25 g (Harlan, Bicester, U.K.) were
maintained in individual cages (width 24.5 cm, length 41.5 cm, and depth 18.5
cm) at 21–23°C with a 12-h light/dark cycle with ad libitum access to food
(RM1 diet; SDS, Witham, U.K.) and water unless specified in procedure
protocol.
Diet-induced obese mice. Studies were performed in C57BL/6 mice when
they had developed diet-induced obesity and their body weight was stable (see
supplementary Methods 1, available in an online appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db09-1198/DC1). Animal studies were
approved under British Home Office Scientific Procedures Act 1986.
Effect of nutritional status on hypothalamic PK2 mRNA expression
rats. Three groups of rats (ad libitum fed, fasted for 12 or 24 h, n  24) were
killed at the beginning of the light phase. Whole hypothalami were dissected
and total RNA was extracted using an RNAqueous-4PCR kit (Applied Biosys-
tems, Austin, TX) according to the manufacturer’s protocol. cDNA was
synthesized from 0.5 g of RNA using a High Capacity cDNA Reverse
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Transcription Kit (Applied Biosystems) according to the manufacturer’s
protocol. Quantitative real-time PCR was performed in triplicate using the
following primer sets: 18S RNA primer assay ID:4310893E, PK2 primer assay
ID:Rn00593837_m1.
Effect of ICV administration of PK2 on food intake. ICV cannulation was
performed as previously described (22). Male rats (n  10–12/group) were
injected intracerebroventricularly with saline or PK2 at doses of 0.005, 0.015, 0.05,
and 0.15 nmol/rat at the beginning of the dark phase. All rats were injected within
a single 20-min period with individual times of injection noted. The subsequent
measurements of food intake are relative to the recorded injection time. Food
intake was measured 1, 2, 4, 8, and 24 h after injection for these studies.
In a second study, rats (n  10–12/group) were injected intracerebroven-
tricularly with saline or PK2 at doses of 0.15, 0.5, and 1.5 nmol/rat at the
beginning of the dark phase. To determine whether PK2 has anorectic effects
in animals refeeding after a fast, rats (n  10–12/group) fasted for 24 h were
injected intracerebroventricularly in the early light phase with saline or PK2 at
doses of 0.15, 1.5, or 4.5 nmol/rat. Food intake was measured 1, 2, 4, 8, and 24 h
after injection for these studies.
Effect of ICV administration of PK2 on locomotor activity. Rats (n 
10–12/group) were injected intracerebroventricularly with saline or PK2 1.5
nmol/rat at the beginning of the dark phase. This dose of PK2 was used
because it potently reduced food intake. The ambulatory activity of each
animal was measured simultaneously using the optical beam technique (Opto
M3; Columbus Instruments, Columbus, OH) (supplementary Methods 2).
Effect of ICV administration of PK2 on behavior. Adult male Wistar rats
weighing 200–250 g (n  10–12/group) were injected intracerebroventricu-
larly with saline or PK2 1.5 nmol/rat and behavioral patterns monitored
continuously for 120 min after injection. Behavior was classified into eight
categories: feeding, drinking, grooming, burrowing, rearing, locomotion, head
down, and sleeping, as previously described (23). Abnormal behavior was
defined by a significant increase in locomotor activity, rearing, head down or
burrowing, or reduced sleeping or grooming, as previously described (23,24).
Effect of ICV administration of PK2 on energy expenditure. Rats (n 
10–12/group) were injected intracerebroventricularly with saline or PK2 1.5
nmol/rat at the beginning of the dark phase and food was removed after
injection but water was available ad libitum. Oxygen consumption was
measured by indirect calorimetry using an open-circuit Oxymax system of the
Comprehensive Lab Animal Monitoring System (Columbus Instruments) (25).
Effect of ICV administration of anti-PK2 antibody on food intake. Rats
(n 10–12/group) were injected intracerebroventricularly with either control
IgG or anti-PK2 antibody (10 or 30 pmol) in the early light phase. Food intake
was measured 1, 2, 4, 8, and 24 h after injection.
Effect of ICV administration of PK2 on c-fos expression. Rats were
cannulated into the lateral ventricle as previously described (26). PK2 (1.5
nmol/rat) or saline (n  4/group) was injected into the lateral ventricle of ad
libitum–fed rats over 1 min in the early light phase. Immunocytochemistry
(ICC) for c-fos was performed on brain sections from animals as previously
described (27). Total numbers of c-fos–positive cells were counted bilaterally
in matched sections from hypothalamic nuclei.
Effect of intranuclear administration of PK2 on food intake. Rats
(200–250 g) had permanent indwelling, unilateral, 26-gauge stainless steel
guide cannulae (Plastics One, Roanoke, VA) stereotactically implanted into
the supraoptic nucleus (SON), arcuate nucleus (ARC), paraventricular nu-
cleus (PVN), anterior hypothalamic area (AHA), ventromedial hypothalamus
(VMH), dorsomedial nucleus (DMN), SCN, and lateral hypothalamic area
(LHA) of the hypothalamus (coordinates listed in supplementary Table 1)
(n 16/nucleus), as previously described (28). The study was of a randomized
crossover design. Each animal received both injections (saline or 0.025 nmol
PK2) in a random order 4 days apart. Food intake was measured 1, 2, 4, 8, and
24 h after injection. The dose of PK2 was chosen based on previous studies
that show that 10% of the effective ICV dose results in significant effects when
directly administered into responsive hypothalamic nuclei and minimizes
nonspecific activation (28). Cannula placement was determined at the end of
the study by injection of Indian ink (28).
Effect of PK2 on the release of neuropeptides known to affect appetite.
Adult male Wistar rats weighing 200–250 g were killed by decapitation and
hypothalamic explants prepared as previously described (29). The hypothal-
ami were incubated for 45 min in 600 l artificial cerebrospinal fluid (aCSF;
basal period). The tissues were then exposed to PK2 (10, 100, or 1,000 nmol/l)
in 600 l aCSF for 45 min (n  9–12/treatment). Finally, the viability of the
tissue was verified by a 45-min exposure to 56 mmol/l KCl. -Melanocyte–
stimulating hormone (-MSH), cocaine and amphetamine–regulated tran-
script, thyrotropin-releasing hormone, corticotrophin-releasing hormone,
neuropeptide Y, and agouti-related peptide (AgRP) in the aCSF were mea-
sured using established radioimmunoassay (22,30–34).
Effect of melanocortin receptor antagonism on the anorectic effects of
PK2. Rats (n  10–12/group) were intracerebroventricularly injected with
either 1) saline, 2) AgRP (1 nmol/rat), 3) -MSH (1 nmol/rat), 4) -MSH (1
nmol/rat) and AgRP (1 nmol/rat), 5) PK2 (0.15 nmol/rat), or 6) PK2 (0.15
nmol/rat) and AgRP (1 nmol/rat) at the beginning of the dark phase. The doses
of -MSH and AgRP were chosen based on previous studies (35). Food intake
was measured 1, 2, 4, 8, and 24 h after injection.
Effect of ICV administration of PK2 on c-fos expression in arcuate
proopiomelanocortin neurons. Animals (n  5 per group) were injected
into the lateral ventricle with 1.5 nmol PK2. In situ hybridization (ISH) for
proopiomelanocortin (POMC) and ICC for c-fos were performed on sections
including the ARC, as previously described (36,37). A riboprobe correspond-
ing to nucleotides 307–795 of the POMC rat sequence (accession no.
NM_139326) was used for ISH. Total numbers of positive cells per animal were
counted from matched sections of the ARC, and colocalized cells were
expressed as a percentage of the total number of POMC and c-fos neurons.
Effect of acute peripheral administration of PK2 on food intake in lean
rats and mice. Rats (n  10–12/group) were injected intraperitoneally with
saline or PK2 at doses of 2.3, 7, or 20 nmol/kg at the beginning of the dark
phase. Food intake was measured 1, 2, 4, 8, and 24 h after injection. Due to the
limited availability of recombinant PK2, the effects of peripheral administra-
tion of PK2 on food intake were further characterized in mice. A similar study
was conducted in groups of C57BL/6 mice (n  10–12/group) injected with
saline or PK2 at doses of 7, 20, 60, 180, or 540 nmol/kg.
Effect of chronic peripheral administration of PK2 on food intake and
body weight in lean and diet-induced obese mice. Adult male C57BL/6
mice weighing 20–25 g (n  10/group) were given twice daily intraperitoneal
injections (early light phase and just prior to the dark phase) of either saline or
PK2 180 nmol/kg for 5 days. Food intake was measured 4 h after the injection at
the beginning of the light phase and 1 h after the injection just prior to the dark
phase. Daily food intake and body weight were also measured.
A similar study was carried out in C57BL/6 diet-induced obese (DIO) mice that
were randomized to 1) saline treatment with ad libitum access to food, 2) PK2
treatment (540 nmol/kg per injection) with ad libitum access to food, or 3)
pair-fed group: saline treatment but food restricted to the daily median food
consumed by the PK2-treated mice over the previous 24-h period (n 10/group).
Statistical analysis. Data are shown as mean values  SEM except c-fos and
behavioral analysis data, which are presented as median and interquartile range.
The studies of food intake and hypothalamic PK2 expression were analyzed using
a one-way ANOVA, followed by post hoc Dunnett test except for the intranuclear
food intake study, which was analyzed using the Holm Bonferroni test. Food
intake data expressed as a change compared with saline-treated animals were
analyzed using a one-way ANOVA, followed by post hoc least significant differ-
ence test. For the c-fos immunocytochemistry and dual ISH/ICC studies, the
Mann-Whitney U test was used. Data from behavioral studies were compared
using Kruskal-Wallis one-way ANOVA on ranks. For the CLAMS (Comprehensive
Laboratory Animal Monitoring System) studies, the generalized estimating equa-
tion and the Mann-Whitney U test were used. In all cases, P  0.05 was
considered statistically significant.
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FIG. 1. Fasting reduces hypothalamic expression of PK2. Hypothalamic
expression of PK2 mRNA among ad libitum–fed, 12-h fasted, and 24-h
fasted rats (n  24 per group) is shown. Results are expressed as
mean  SEM. ***P < 0.001 versus fed group.
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RESULTS
Expression of PK2 is reduced during fasting. The
expression levels of hypothalamic neuropeptides that reduce
food intake (e.g., -MSH) are often elevated in states of
positive energy balance and reduced in states of negative
energy balance (38). Hypothalamic PK2 expression was
significantly reduced by 45% in rats fasted for 12 or 24 h (Fig.
1). This is consistent with the hypothesis that PK2 is an
endogenous anorectic hypothalamic neuropeptide.
PK2 reduces food intake without altering locomotor
activity or energy expenditure. ICV administration of
PK2 caused a dose-dependent significant reduction in food
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FIG. 2. PK2 potently reduces food intake independent of changes in
locomotor activity or energy expenditure. Food intake: Effect on 0–1
h food intake in ad libitum–fed rats (n  10–12 per group) after ICV
administration at the beginning of the dark phase of PK2 at doses of
0.005, 0.015, 0.05, and 0.15 nmol/rat (A). Effect on 0–1 h food intake
in ad libitum–fed rats (n  10–12 per group) after ICV administration
at the beginning of the dark phase of PK2 at doses of 0.15, 0.50, and 1.5
nmol/rat (B). Rats (n  10–12 per group) fasted for 24 h were injected
intracerebroventricularly in the early light phase (C and D) with PK2
at doses of 0.15, 1.5, or 4.5 nmol/rat. Food intake in the first hour (C)
and cumulative food intake for 24 h after injection are shown (D).
Results are expressed as mean  SEM (n  10–12 per group). *P <
0.05, **P < 0.01, ***P < 0.001 versus saline. Locomotor activity: Effect
of ICV injection of saline or PK2 1.5 nmol/rat at the beginning of the
dark phase on horizontal (E) and rearing (F) movement, respectively.
Data are shown as mean  SEM for each 30-min time period (n 
10–12 per group). Horizontal black bar under the x-axis indicates dark phase and open bar indicates light phase. Energy expenditure: Effect
of ICV injection of saline or PK2 1.5 nmol/rat on oxygen consumption (G). Horizontal black bar under the x-axis indicates dark phase and
open bar indicates light phase.
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intake that, at doses greater than 0.15 nmol/rat, produced
an 85% reduction in food consumed in the first hour after
injection (Fig. 2A and B, supplementary Fig. 1, and sup-
plementary Table 2A and B). When administered intrac-
erebroventricularly in the early light phase to fasted rats,
PK2 caused a similarly potent inhibition of food intake
(Fig. 2C and supplementary Table 2C). In addition, rats
injected with 1.5 and 4.5 nmol PK2 had a 30% reduction in
24-h food intake compared with saline-injected rats (Fig.
2D and supplementary Table 2C).
A reduction in food intake can be due to an indirect
effect, for example, changes in locomotor activity or
behavior (39). ICV administration of PK2 to ad libitum–fed
rats did not significantly alter locomotor activity or
result in abnormal behavior compared with saline-
injected animals (Fig. 2E and F and supplementary
Table 3). However, consistent with an increase in sati-
ety, ICV PK2 significantly reduced the number of feeding
episodes (supplementary Table 3). Many regulators of
food intake also regulate energy expenditure. However,
this does not appear to be the case for PK2, because ICV
administration of PK2 did not alter oxygen consump-
tion, a surrogate for energy expenditure (Fig. 2G). These
data suggest that ICV administration of PK2 specifically
reduces food intake for up to 24 h.
Immunoblockade of endogenous hypothalamic PK2
increases food intake. Rats injected with anti-PK2 anti-
body ate significantly more than rats injected with control
IgG antibody, suggesting that endogenous PK2 may re-
strain appetite (Fig. 3 and supplementary Table 4).
PK2 reduces food intake via specific hypothalamic
nuclei. ICV administration of PK2 resulted in a significant
increase in c-fos immunoreactivity in the SON, ARC, PVN,
and AHA (Fig. 4A–F). No significant changes in c-fos
expression were observed in the VMH, DMN, SCN, or LHA
(Fig. 4A and supplementary Fig. 2).
To establish which hypothalamic nuclei mediate PK2’s
anorectic effects, PK2 was administered into the hypotha-
lamic nuclei showing c-fos activation after ICV adminis-
tration of PK2. In addition, other nuclei expressing PKR2
were also injected with PK2 as negative controls. PK2
significantly reduced 0–1 h food intake in rats after
administration into the SON, ARC, PVN, and AHA (Fig.
4G), but there was no significant effect of PK2 after
injection into the VMH, DMN, SCN, or LHA (Fig. 4G).
PK2 mediates part of its anorectic effects via the
melanocortin system. PK2 significantly stimulated the
release of -MSH (Fig. 5A) but did not alter the release of
the other hypothalamic neuropeptides measured (supple-
mentary Table 5).
We therefore hypothesized that ICV PK2 may mediate
part of its anorectic effect via the melanocortin system. To
further investigate the relationship between PK2 and the
melanocortin system in vivo, we coadministered AgRP
with PK2. In this paradigm, AgRP attenuated the effect of
PK2, suggesting that PK2 may reduce food intake in part
via the melanocortin system (Fig. 5B). To confirm that the
dose of AgRP used was antagonizing -MSH, we demon-
strated that ICV administration of -MSH reduced 0–2 h
food intake in rats, whereas coadministration of AgRP
with the same dose of -MSH abolished the anorectic
effect of -MSH (Fig. 5B).
To determine whether ICV administration of PK2 re-
sulted in activation of ARC POMC neurons (which pro-
duce -MSH), we performed colocalization studies of c-fos
and POMC after ICV administration of PK2. ICV administra-
tion of PK2 significantly increased the number of arcuate
POMC-expressing neurons exhibiting c-fos immunoreactivity
(Fig. 5C and Table 1). Together these data suggest that PK2
may mediate part of its anorectic effect via the ARC melano-
cortin system.
Peripheral administration of PK2 acutely reduces
food intake in rats and C57BL/6 mice
Rats. A single intraperitoneal injection of PK2 (20 nmol/
kg) reduced food intake by 45% in the first hour after
injection but did not affect food intake at the other time
points studied (Fig. 6A and supplementary Table 6A).
C57BL/6 mice. Intraperitoneal injection of PK2 in mice
reduced 0–1 h food intake at similar doses to those in rats
(Fig. 6B). Higher doses of PK2 in mice resulted in a further
dose-dependent reduction in food intake for up to 24 h
after injection (Fig. 6B and supplementary Table 6B). The
highest dose of PK2 (540 nmol/kg) administered produced
a 20% reduction in 24-h food intake (Fig. 6C and supple-
mentary Table 6B).
Chronic peripheral administration of PK2 decreases
food intake and body weight in lean and obese mice
Lean mice. Twice daily intraperitoneal injection of PK2
for 5 days in lean mice significantly decreased cumulative
food intake (Fig. 7A) and body weight compared with
saline-injected controls (Fig. 7B). The reduction in food
intake after each single injection of PK2 was similar in
magnitude throughout the study period, suggesting that
PK2 remained equally potent after recurrent administra-
tion (supplementary Table 7).
DIO mice. DIO mice are commonly used as a rodent
model of human obesity (40). Some anorectic factors, for
example leptin, are ineffective in obese mice (41). To
investigate whether DIO mice were sensitive to PK2, we
administered PK2 twice daily by intraperitoneal injection
for 5 days to DIO mice. PK2 significantly reduced cumu-
lative food intake (Fig. 7C) and body weight (Fig. 7D)
compared with saline-injected controls. DIO mice pair fed
to the PK2-treated group lost a similar amount of body
weight as the mice given PK2 (Fig. 7D), suggesting the
effect of PK2 on body weight was mediated predominantly
via a reduction in food intake. As in lean mice, injection of
PK2 was equally potent at reducing food intake on each of
the 5 days of the study (supplementary Table 8). These
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FIG. 3. Immunoblockade of endogenous PK2 increases food intake. The
effect on 2–4 h food intake of ICV administration of control IgG or
anti-PK2 antibody (10 or 30 pmol) to satiated rats (n  10–12 per
group) at the beginning of the light phase. Results are expressed as
mean  SEM. *P < 0.05 versus 30 pmol control IgG group.
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FIG. 4. PK2 mediates its effects via specific hypothalamic nuclei. A: Graphical representation of c-fos activation in hypothalamic nuclei of rats after
administration of saline or PK2 (1.5 nmol/rat) into the lateral ventricle. Open bars represent saline-injected animals; filled gray bars, PK2-injected
animals. Data are shown as median and interquartile range. SON, supraoptic nucleus; ARC, arcuate nucleus; PVN, paraventricular nucleus; AHA,
anterior hypothalamic area; SCN, suprachiasmatic nucleus; VMH, ventromedial hypothalamus; LHA, lateral hypothalamic area; DMN, dorsomedial
nucleus. *P < 0.05 versus saline. B–F: Representative brain sections showing c-fos expression in the SON (B), ARC (C), PVN (D), and AHA (E and F)
of rats injected into the lateral ventricle with saline or PK2 (1.5 nmol/rat). Scale bar, 100 m. Brain sections from rats injected with saline are shown
in the panels on the left and those from rats injected with PK2, in the panels on the right. Representative brain sections showing c-fos expression in
the VMH, DMN, SCN, and LHA are shown in supplementary Fig. 1. G: Effects on food intake of saline or PK2 (0.025 nmol/rat) injection into specific
hypothalamic nuclei at the beginning of the dark phase into rats. Food intake consumed in the first hour after PK2 injection (black bar) is shown as
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data suggest that repeated administration of PK2 results in
reduced food intake and body weight without tachyphy-
laxis in lean and obese mice.
DISCUSSION
The hypothalamus is a key center of the brain involved in
appetite regulation. PK2 and its receptors are expressed in
hypothalamic nuclei known to affect food intake, but the
effect of PK2 on food intake has not previously been
reported. Our data suggest that PK2 is a novel hypotha-
lamic anorectic neuropeptide. It was important to deter-
mine whether the anorectic effects of PK2 were due to
behavioral changes because PK2- or PKR2-null mice dis-
play abnormal circadian rhythms and locomotor activity
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(16–18). ICV administration of PK2 potently inhibited food
intake in rats up to 24 h after injection, but did not alter
locomotor activity or cause abnormal behaviors. These
data suggest the anorectic effects of PK2 are not secondary
to effects on locomotor activity or other behavioral
abnormalities.
To investigate the possibility that endogenous PK2 may
affect appetite, we determined the effect of immunoblock-
ade of endogenous hypothalamic PK2 in rats. ICV admin-
istration of PK2 antibody in the early light phase (when
endogenous CNS PK2 levels are highest [14]) increased
food intake in rats, suggesting that elevated CNS PK2
signaling may inhibit food intake in the light phase.
However, this finding needs to be interpreted with caution
because the increase in food intake after ICV administra-
tion of PK2 antibody was small. Conversely, CNS PK2
expression is at its lowest in the dark phase, and this
reduction in PK2 inhibitory tone may therefore contribute
to the nocturnal increase in food intake. Our results also
show that hypothalamic PK2 mRNA expression was lower
in fasted rats compared with ad libitum–fed rats, support-
ing the hypothesis that PK2 may act as an endogenous
anorectic signal.
If PK2 is an endogenous inhibitor of food intake, one
might expect PK2-null mice to be obese. Mice lacking PK2
have not been reported to have increased body weight
compared with their wild-type littermates (8,16). However,
PK2 is critical in CNS development and these mice have
reduced voluntary and spontaneous locomotor activities,
show a reduction in the time spent sleeping compared
with wild-type mice (16), and have reduced fertility (11).
These factors are likely to confound the effects of the lack
of PK2 signaling on energy homeostasis in this mouse
model. In addition, it is known that developmental com-
pensation in embryonic knockout models of appetite-
regulating factors can mask roles in energy homeostasis,
for example, as has been suggested to occur with neu-
ropeptide Y and AgRP (42). A postembryonic or condi-
tional knockout model of PK2, or animal studies in which
local hypothalamic PK2 expression is reduced, may help
TABLE 1
Expression of c-fos in arcuate POMC neurons after ICV administration of PK2
Treatment
Total POMC
cell counts
Total c-fos cell
counts
Colocalized
POMC/c-fos
cell counts
% POMC cells
colocalized
with c-fos
% c-fos cells
colocalized
with POMC
Saline 425 (424–435) 12 (7–18) 5 (4–7) 1.2 0.3 48.1 5.5
PK2 440 (412–446) 51 (26–65)* 32 (16–33)† 7.0 1.4 64.0 6.6
Data are median (interquartile range) from matched sections throughout the ARC. Colocalized labeling is expressed as a percentage as
mean  SE. *P  0.05 versus saline; †P  0.01 versus saline; n  5 per group.
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to further determine the role of endogenous PK2 in
appetite regulation.
To investigate the hypothalamic sites that may mediate
the anorectic effects of PK2, we used the induction of c-fos
as a marker of neuronal activation (43). ICV administra-
tion of PK2 resulted in c-fos induction in the SON, ARC,
PVN, and AHA, and direct injection of PK2 into each of
these nuclei reduced food intake, suggesting that the
anorectic effects of PK2 may be mediated directly via these
nuclei. After ICV administration of PK2 and direct injec-
tion of PK2 into the VMH, DMN, SCN, or LHA, which all
express prokineticin receptors, there was no induction of
c-fos and PK2 did not significantly affect food intake.
These data suggest that the anorectic effects of PK2 may
be mediated via specific hypothalamic pathways.
ICV administration of PK2 induced c-fos expression in
the ARC and direct injection of PK2 into the ARC reduced
food intake, suggesting that ICV PK2 may mediate part of
its anorectic effect via the ARC. PK2 may therefore medi-
ate its anorectic effects via alteration in hypothalamic ARC
neuropeptides. Our results show that PK2 increased the
release of -MSH from hypothalamic explants ex vivo and
ICV coadministration of AgRP with PK2 attenuated the
anorectic effects of PK2. Consistent with this, ICV admin-
istration of PK2 resulted in c-fos activation in ARC POMC
neurons that produce -MSH. Together these data suggest
that PK2 may mediate part of its anorectic effect via the
hypothalamic ARC melanocortin system.
To investigate whether peripheral administration of PK2
had anorectic effects, we investigated the effects of intra-
peritoneal administration of PK2 on food intake and body
weight in rodents. Peripheral administration of PK2
acutely reduced food intake with similar efficacy in rats
and mice. This led us to investigate whether repeated PK2
administration would result in a sustained reduction in
food intake and body weight, since repeated administra-
tion of anorectic agents can cause tachyphylaxis (44),
resulting in an attenuated effect after repeated administra-
tion. PK2 administration to lean or obese mice caused a
similar reduction in food intake after each injection and
resulted in a significant reduction in body weight, suggest-
ing that tachyphylaxis to the anorectic effects of PK2 does
not occur using this administration protocol.
Leptin reduces food intake and body weight in lean
animals but is ineffective in obese animals (41). This may
be due to differences between the appetite circuits of lean
and obese animals (45) and/or the development of resis-
tance to leptin in obese animals (46). We therefore inves-
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tigated the effect of repeated intraperitoneal PK2
administration in DIO mice, which are commonly used as
a model of human obesity (40). PK2 resulted in a similar
reduction in food intake after each injection, and reduced
cumulative food intake and body weight in DIO mice.
Higher doses of PK2 were required to reduce food intake
in DIO mice than in lean mice, but this resulted in greater
weight loss in DIO mice compared with lean mice.
In both lean and DIO mice, the effect of PK2 on body
weight is likely to be mediated predominantly via a reduc-
tion in food intake because control mice pair fed to
PK2-injected mice lost a similar amount of weight as the
PK2-injected group. This is consistent with our studies in
rats in which ICV administration of PK2 reduced food
intake without affecting energy expenditure. In addition, it
is unlikely that this effect is due to an acute reduction in
water intake because the prokineticin receptor agonist
Bv8 has actually been shown to slightly increase, rather
than reduce, water intake (19). This phenomenon of a
rapid weight loss on the first day is widely observed in
investigations of anorectic agents. The rapid decrease is
thought to occur as a result of the rapid utilization of
glycogen stores, and is especially true in rodents. The
decrease is followed by a period in which fat is lost,
coinciding with the less rapid weight loss (47,48).
In summary, our data identify a novel role for PK2 in
appetite regulation. The anorectic effects of PK2 appear to
be mediated in part via the ARC melanocortin system.
Repeated peripheral administration of PK2 for 5 days
reduced food intake and body weight in obese mice.
Further studies investigating the effects of longer term
administration of PK2 on food intake and body weight will
determine the potential of PK2 as a target for the devel-
opment of antiobesity agents.
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